Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly reduced prices following the expiration of Boehringer Ingelheim’s patent. Mankind Pharma’s version is priced at Rs 5.50 per tablet, a reduction of 90%. This move is expected to improve access to affordable diabetes treatment in India.
